Belite Bio (BLTE) CEO & Chairman reports 1.25M shares, including vested awards

Rhea-AI Filing Summary

Belite Bio, Inc. reports a beneficial ownership statement for Yu-Hsin Lin. The filing shows 1,253,935 Ordinary Shares beneficially owned by Mr. Lin, equal to 3.1% of the class. The filing states the company had 40,085,091 Ordinary Shares outstanding as of March 31, 2026.

The notes state Mr. Lin is deemed to hold a total of 2,728,462 Ordinary Shares when including (i) 353,083 shares directly held, (ii) 900,852 shares underlying vested or soon-to-vest options and RSUs, and (iii) 1,474,527 shares held indirectly through Lin BioScience, Inc. Mr. Lin disclaims investment and disposition power over the indirect holdings.

Insights

Governance Analyst

Insider ownership disclosure clarifies direct, derivative, and indirect holdings.

The amendment lists 1,253,935 Ordinary Shares as the amount Mr. Lin reports having sole voting and dispositive power over, representing 3.1% of the class based on 40,085,091 outstanding shares as of March 31, 2026. It also details an expanded beneficial position of 2,728,462 shares when vested options and indirect holdings are included.

Key dependencies are the vesting schedule for 900,852 share-equivalents and the reporting person’s disclaimer about indirect holdings through Lin BioScience, Inc. Subsequent filings will show changes if vested options are exercised or indirect holdings shift.

Securities Compliance Specialist

Disclosure follows beneficial-ownership conventions and clarifies voting/disposition powers.

The filing specifies sole voting and sole dispositive power over 1,253,935 shares and records the calculation basis that includes share equivalents that vest within 60 days. It preserves the reporting person’s disclaimer regarding 1,474,527 indirectly held shares.

Compliance implications: the statement aligns ownership calculations with the issuer-provided outstanding share count. Future Schedule 13 filings will reflect any exercises, vesting, or transfers that change these counts.

Key Figures

Amount beneficially owned: 1,253,935 shares Percent of class: 3.1% Shares outstanding: 40,085,091 shares +4 more

7 metrics

Amount beneficially owned 1,253,935 shares reported beneficial ownership amount

Percent of class 3.1% percent of class based on outstanding shares as of March 31, 2026

Shares outstanding 40,085,091 shares issued and outstanding as of March 31, 2026

Deemed holdings including awards 2,728,462 shares total deemed to be held when including direct, vested/vesting awards, and indirect holdings

Directly held shares 353,083 shares shares directly held by Yu-Hsin Lin

Options and RSUs vesting 900,852 shares share equivalents vested or vesting within 60 days of March 31, 2026

Indirect holdings 1,474,527 shares held indirectly through Lin BioScience, Inc.

Key Terms

beneficially owned, restricted stock units (RSUs), disclaims investment and disposition power, vesting within 60 days

4 terms

beneficially owned regulatory

"Amount beneficially owned: 1,253,935"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

restricted stock units (RSUs) financial

"900,852 Ordinary Shares underlying share options and restricted stock units"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

disclaims investment and disposition power regulatory

"Yu-Hsin Lin disclaims investment and disposition power of the 1,474,527"

vesting within 60 days financial

"vested or will be vested within 60 days of March 31, 2026"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:00 PM Learn about SEC filing dates

FAQ

What stake does Yu-Hsin Lin hold in Belite Bio (BLTE)?

Yu-Hsin Lin reports 1,253,935 Ordinary Shares, representing 3.1% of the class based on 40,085,091 shares outstanding as of March 31, 2026. The filing also notes a broader deemed holding of 2,728,462 shares including vested/vesting awards and indirect holdings.

How is the 2,728,462 shares figure for Mr. Lin composed?

The filing states the total includes 353,083 shares directly held, 900,852 shares underlying options and RSUs that are vested or vest within 60 days, and 1,474,527 shares held indirectly through Lin BioScience, Inc.

Does Mr. Lin control the indirectly held shares?

The filing explicitly states Mr. Lin disclaims investment and disposition power over the 1,474,527 indirectly held Ordinary Shares through Lin BioScience, Inc. It reports sole voting and dispositive power only over the 1,253,935 shares listed.

What outstanding share count does the filing use for percentage calculations?

The percentage is calculated using an aggregate of 40,085,091 Ordinary Shares issued and outstanding as of March 31, 2026 and the 900,852 share equivalents that vest within 60 days, per the filing's notes.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

BELITE BIO, INC

(Name of Issuer)

Ordinary shares, par value US$0.0001 per share

(Title of Class of Securities)

07782B104

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 07782B104

1

Names of Reporting Persons

Yu-Hsin Lin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

AUSTRALIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,253,935.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,253,935.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,253,935.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.1 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Notes to row 9: Yu-Hsin Lin is deemed to hold a total of 2,728,462 Ordinary Shares in Belite Bio, Inc, among which (i) 353,083 Ordinary Shares are directly held by Yu-Hsin Lin; (ii) 900,852 Ordinary Shares underlying share options and restricted stock units granted to Yu-Hsin Lin that are vested or will be vested within 60 days of March 31, 2026 are deemed to be held by Yu-Hsin Lin; and (iii) 1,474,527 Ordinary Shares are indirectly held by Yu-Hsin Lin through his shareholding in Lin BioScience, Inc., a public company listed on the OTC market in Taiwan (stock code: 6696.TW) and the parent company of Lin Bioscience International Ltd. Yu-Hsin Lin disclaims investment and disposition power of the 1,474,527 Ordinary Shares indirectly held by Yu-Hsin Lin through Lin BioScience, Inc. and Lin Bioscience International Ltd. Notes to row 11: The percentage is calculated by dividing the number of Ordinary Shares beneficially owned by Yu-Hsin Lin by the aggregate of (i) 40,085,091 Ordinary Shares issued and outstanding as of March 31, 2026 as provided by the Issuer; and (ii) 900,852 Ordinary Shares underlying share options and restricted stock units granted to Yu-Hsin Lin that are vested or will be vested within 60 days of March 31, 2026 and are deemed to be beneficially owned by Yu-Hsin Lin.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BELITE BIO, INC
(b)	Address of issuer's principal executive offices: 12750 High Bluff Drive Suite 475, San Diego, CA 92130, United States of America
Item 2.
(a)	Name of person filing: This Schedule 13G is filed on behalf of Yu-Hsin Lin ("Reporting Person")
(b)	Address or principal business office or, if none, residence: The business address of the Reporting Person is 36F., No. 68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan
(c)	Citizenship: Yu-Hsin Lin is a citizen of Australia
(d)	Title of class of securities: Ordinary shares, par value US$0.0001 per share
(e)	CUSIP No.: 07782B104
Item 4.	Ownership
(a)	Amount beneficially owned: 1,253,935
(b)	Percent of class: 3.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,253,935
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,253,935
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Yu-Hsin Lin

Signature:	/s/ Yu-Hsin Lin
Name/Title:	Yu-Hsin Lin, Chief Executive Officer and Chairman
Date:	05/14/2026